Cytek Biosciences, Inc. - Common Stock (CTKB)
4.1800
+0.00 (0.00%)
NASDAQ· Last Trade: Aug 6th, 5:49 AM EDT
Cytek Biosciences (NASDAQ:CTKB) reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and parts of Asia-Pacific limited overall growth.
Revenue for the quarter ended June 30 was $48.1 mill
Via MarketBeat · August 5, 2026
Cytek (CTKB) Q1 2026 Earnings Call Transcript
Via The Motley Fool · May 8, 2026

Cytek (CTKB) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 27, 2026
Cytek Biosciences Inc (NASDAQ:CTKB) Reports Q4 2025 Revenue Beat and Mixed Earningschartmill.com
Via Chartmill · February 26, 2026

Via Benzinga · May 28, 2025
Via Benzinga · November 14, 2025
Cytek (CTKB) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 5, 2025

Via Benzinga · May 28, 2025

Via Benzinga · December 30, 2024

Via Benzinga · December 30, 2024

Via Benzinga · November 19, 2024

Via Benzinga · November 6, 2024

Via Benzinga · November 6, 2024

Via Benzinga · November 6, 2024

Via Benzinga · November 6, 2024

CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024

CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024

CTKB stock results show that Cytek Biosciences beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 27, 2024

U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday.
Via Benzinga · March 4, 2024


